PHASE II, OPEN-LABEL STUDY TO ESTIMATE THE OVERALL RESPONSE RATES OF OLAPARIB IN SUBJECTS WITH RECURRENT/PROGRESSIVE IDH1/2-MUTANT SOLID TUMORS IN 3 COHORTS (GLIOMA, CHOLANGIOCARCINOMA, AND OTHER SOLID MALIGNANT TUMORS).